MedTrace Logo

Helicobacter Pylori Immune Thrombocytopenic Purpura

NCT01255332 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2010-12-07

No results posted yet for this study

Summary

We designed a study for evaluate the efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenic purpura (ITP) patients with moderate thrombocytopenia.

If this eradication treatment is revealed effective on ITP patients with more than 30X109/L of platelet, it would be valuable treatment especially for young ITP patients with mild to moderate thrombocytopenia.

Conditions

  • Immune Thrombocytopenic Purpura

Sponsors & Collaborators

  • Cooperative Study Group A for Hematology

    lead NETWORK

Principal Investigators

  • Jung-Hee Lee, professor · Asan Medical Center

  • Hyo Jung Kim, professor · Department of Internal Medicine, Hallym University Sacred Heart Hospital

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-08-31
Completion
2012-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01255332 on ClinicalTrials.gov